Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of EGFR (epidermal growth factor receptor) inhibitor and anti-angiogenesis medicine in medicine for treating tumor diseases

An inhibitor and anti-vascular technology, applied in the field of medicine, can solve the problems of drug resistance and no clinical treatment plan in patients with non-small cell lung cancer

Pending Publication Date: 2022-03-18
SHANGHAI HANSOH BIOMEDICAL +1
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, regardless of the first-generation EGFR inhibitors represented by Gefitnib, the second-generation EGFR inhibitors represented by Afatinib, and the third-generation EGFR inhibitors represented by Osimertinb (AZD9291), after long-term clinical use in non- Drug resistance emerges in patients with small cell lung cancer
At present, there is no good clinical treatment plan for the above-mentioned drug-resistant patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of EGFR (epidermal growth factor receptor) inhibitor and anti-angiogenesis medicine in medicine for treating tumor diseases
  • Application of EGFR (epidermal growth factor receptor) inhibitor and anti-angiogenesis medicine in medicine for treating tumor diseases
  • Application of EGFR (epidermal growth factor receptor) inhibitor and anti-angiogenesis medicine in medicine for treating tumor diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0090] 1. Purpose of the experiment:

[0091] To evaluate the experimental therapeutic effect of Almonertinib combined with anti-angiogenic drug BP102 (bevacizumab biosimilar) on human lung cancer PC-9 xenografts in nude mice.

[0092] 2. Experimental materials:

[0093] 2.1 Test drug:

[0094] Drug A: Almonertinib (the mesylate salt of the compound of formula (I)), prepared according to the method disclosed in WO2017161937, and pH 4.18 acetate buffer is used for drug preparation;

[0095] Drug B: bevacizumab biosimilar (BP102), injection, Suzhou Shengdia Biomedical Co., Ltd.

[0096] 2.2 Experimental reagents:

[0097] PC-9 cells were purchased from Guangzhou Geneo Biotechnology Co., Ltd. 150cm 2 The culture flask adheres to the wall, and the culture condition is RPMI1640 medium plus 10% fetal bovine serum and 1% streptomycin / penicillin, at 37 ° C, containing 5% CO 2 cultured in an air incubator. Subculture 1-2 times a week, when the cells are in the exponential growth...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of an EGFR (epidermal growth factor receptor) inhibitor and an anti-angiogenesis medicine in a medicine for treating tumor diseases. Specifically, the invention provides an application of a human epidermal growth factor receptor inhibitor (EGFRi) combined anti-angiogenesis medicine in a medicine for preventing or treating tumor diseases.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to the use of EGFR inhibitors and anti-angiogenesis drugs in drugs for treating tumor diseases. Background technique [0002] Worldwide, lung cancer has become the main cause of cancer death, and its morbidity and mortality are on the rise. In 2012, there were about 1.8 million new cases of lung cancer in the world. However, by 2018, the number of diagnosed cases of lung cancer in the world increased to 2.1 million. In China, in terms of incidence rate, statistics from the China Cancer Center show that lung cancer ranks first in the country, with about 781,000 cases per year, accounting for 20.55% of all types of cancer; in terms of mortality, lung cancer, liver cancer, gastric cancer , Esophageal cancer is the main cause of death of tumors. Despite the introduction of newer generations of cytotoxic drugs and targeted therapies over the past 20 years, treatment options and survival in patient...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/506A61K39/395A61P35/00A61P35/02
CPCA61K45/06A61K31/506A61K39/3955A61P35/00A61P35/02A61K2039/545A61K2300/00
Inventor 周远锋张晓婷
Owner SHANGHAI HANSOH BIOMEDICAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com